In hereditary neuropathy, "uniform conduction block" was once thought to be a characteristic in contrast to "non-uniform conduction block". Uniform conduction block is characterized by conduction block without any temporal dispersion. Now this is only seen CMT 1A hereditary neuropathy. Non-uniform conduction block is seen in other hereditary neuropathies and acquired demyelinating neuropathy. In the recent years, uniform conduction block is also observed in "axonal form of GBS" (AMAN and AMSAN), Some called this "axonal conduction block". This is misnomer. This is discussed in my recent paper in Muscle Nerve in 2021 Feb issue.

When talking about clinical meaningful change in blood pressure and heart this is very subjective. You would need to know if any medication affects the body's ability to change these parameters. Heart rate and blood pressure are both required for Cardiac output. So if one is being suppressed or elevated the other may be affected as well. As for SpO2, Clinically the goal for any age is never below 88-90%. I hope this helps.

Stephanie Bartlett thank you for your response. im not sure your answer is in the right context. I am only interested in looking at MCID for those parameters in response to rehabilitation in an ITU setting not necessarily in response to pharmacology generally. My basic question is what is a clinical change in those parameters that would warrant a change in how physios manage patients on ITU from a safety perspective.

bw

New 2021 guidelines ViItal signs handbook https://cardiopt.memberclicks.net/assets/docs/CPG/Joint%20Vital%20Sign%20Booklet.pdf